IEHP UM Subcommittee Approved Authorization Guidelines Electroconvulsive Therapy- ECT

Similar documents
ADMINISTRATIVE POLICY AND PROCEDURE

10801 Sixth St, Rancho Cucamonga, CA Tel (909) Fax (909) Visit our web site at:

IEHP UM Subcommittee Approved Authorization Guidelines Referrals to Pain Management Specialists

IEHP UM Subcommittee Approved Authorization Guidelines Referrals to Pain Management Specialists

Adult Mental Health Services applicable to Members in the State of Connecticut subject to state law SB1160

IEHP UM Subcommittee Approved Authorization Guidelines Intravenous Sedation and General Anesthesia Coverage for Dental Services

IEHP UM Subcommittee Approved Authorization Guidelines Magnetic Resonance Spectroscopy

VO- PMHP Treatment Guideline 102: Electroconvulsive Therapy (ECT)

IEHP UM Subcommittee Approved Authorization Guideline Guideline Intravenous Sedation and General Guideline # UM_DEN 01. Date

Admission Criteria Continued Stay Criteria Discharge Criteria. All of the following must be met: 1. Member continues to meet all admission criteria

Are they still doing that?

Help and Healing: Section 2: Treatment Planning. Treatment and Timelines. Depression Treatment Reference. Care Team Communication

(Rescinds MCCMH Policy )

Some newer, investigational approaches to treating refractory major depression are being used.

Electroconvulsive Therapy Prior Authorization Request

IEHP UM Subcommittee Approved Authorization Guidelines Colorectal Cancer Screening with Cologuard TM for Medicare Beneficiaries

Clinical Policy Title: Ketamine for treatment-resistant depression

CALIFORNIA COUNTIES TREATMENT RECORD REQUIREMENTS

Transcranial Magnetic Stimulation

Neuromodulation Approaches to Treatment Resistant Depression

Medical Necessity Criteria

Bipolar Disorder Clinical Practice Guideline Summary for Primary Care

Clinical UM Guideline

Aging with Bipolar Disorder. Neha Jain, MD, FAPA Assistant Professor of Psychiatry, UConn Health

Practice parameter for use of electroconvulsive therapy with adolescents.

Frequently Asked Questions FAQS. NeuroStar TMS Therapies

Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents

IEHP UM Subcommittee Approved Authorization Guidelines DEXA Scan

See Important Reminder at the end of this policy for important regulatory and legal information.

Adult Mental Health Services Applicable to insured members in the State of Connecticut subject to state law SB1160

Psychotropic Medication

ELECTROCONVULSIVE THERAPY (ECT)

Depression Disease Navigation

Community Services - Eligibility

Inpatient Psychiatric Services for Under Age 21 Manual. Acute Inpatient Mental Health (Child/Adolescent)

IEHP UM Subcommittee Approved Authorization Guidelines Proton Beam Radiation Therapy for Prostate Cancer

Adherence in A Schizophrenia:

ADMINISTRATIVE POLICY AND PROCEDURE

Psychotropic Medication. Including Role of Gradual Dose Reductions

Guidelines for the Utilization of Psychotropic Medications for Children in Foster Care. Illinois Department of Children and Family Services

MEDICAL POLICY EFFECTIVE DATE: 04/28/11 REVISED DATE: 04/26/12, 04/25/13, 04/24/14, 06/25/15, 06/22/16, 06/22/17

REQUEST FOR MEDICARE PRESCRIPTION DRUG COVERAGE DETERMINATION This form may be sent to us by mail or fax:

IEHP considers the treatment of obstructive sleep apnea (OSA) medically necessary according to the criteria outlined below:

Corporate Medical Policy

The New Clinical Science of ECT

Clinical Policy: Digital Breast Tomosynthesis Reference Number: CP.MP.90

UnitedHealthcare Community (UHCCP) Louisiana Clinical Program Guidelines Record Supplemental Tool

Alcohol Opiates Other:

MEDICAL POLICY No R8 EATING DISORDERS POLICY/CRITERIA

Nonpharmacologic Interventions for Treatment-Resistant Depression. Public Meeting December 9, 2011

See Important Reminder at the end of this policy for important regulatory and legal information.

Statement on Electroconvulsive Therapy (ECT) Position statement CERT01/17

Clinical Policy: Olanzapine Orally Disintegrating Tablet (Zyprexa Zydis) Reference Number: CP.PMN.29 Effective Date: Last Review Date: 02.

ECT in children and adolescents

Clinical Policy: Gastric Electrical Stimulation Reference Number: CP.MP.40

Legal 2000 and the Mental Health Crisis in Clark County. Lesley R. Dickson, M.D. Executive Director, Nevada Psychiatric Association

It is the policy of health plans affiliated with Centene Corporation that Seroquel XR is medically necessary when the following criteria are met:

Information about ELECTROCONVULSIVE THERAPY (ECT)

See Important Reminder at the end of this policy for important regulatory and legal information.

We know you will have questions

CIGNA STANDARDS AND GUIDELINES/MEDICAL NECESSITY CRITERIA

Electroconvulsive therapy and its place in the management of depression Ankush Singhal MD, MRCPsych

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Oregon. Retirement Date N/A

Oscar G. Morales. MD Founding Director McLean Hospital TMS

Psychopharmacology 1: ECT

The New England Comparative Effectiveness Public Advisory Council. Public Meeting December 9, 2011

CIRCULAR 58 OF 2018 : BENEFIT DEFINITION SUBMISSIONS FOR SCHIZOPHRENIA, BIPOLAR MOOD DISORDER AND MENTAL HEALTH EMERGENCIES

Yescarta (axicabtagene ciloleucel)

FDA Executive Summary. Meeting to Discuss the Classification of Electroconvulsive Therapy Devices (ECT)

Date: Dear Mental Health Professional,

Review: Psychosocial assessment and theories of development from N141 and Psych 101

American Board of Psychiatry and Neurology, Inc. Geriatric Psychiatry Core Competencies Outline

Clinical Policy: Clozapine orally disintegrating tablet (Fazaclo) Reference Number: CP.PMN.12 Effective Date: Last Review Date: 02.

Bock Associates 221 West 2 nd Street, Suite 607 Little Rock, AR 72201

Depression: Assessment and Treatment For Older Adults

Condensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia

12/17/2012. Unnecessary Drugs

Topical Oxygen Wound Therapy (MEDICAID)

See Important Reminder at the end of this policy for important regulatory and legal information.

What s new in the treatment of bipolar disorder?

Antidepressants for treatment of depression.

PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA

THE PRACTICE OF ECT. Kiran Rabheru

IEHP UM Subcommittee Approved Authorization Guidelines Liver Biopsy in Conjunction with Bariatric Surgery

Clinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: CP.MP.145

SOUND HEALTH & WELLNESS TRUST

rtms Versus ECT The Future of Neuromodulation & Brain Stimulation Therapies

Medical Necessity Criteria

Electro-Convulsive Therapy Goals. Electro-Convulsive Therapy: Update Ambulatory Surgery Center at UCSF. Outline

Bock Associates 221 West 2 nd Street, Suite 607 Little Rock, AR 72201

CLINICAL MEDICAL POLICY

See Important Reminder at the end of this policy for important regulatory and legal information.

ACUTE INPATIENT TREATMENT

Clinical Guideline for the Management of Bipolar Disorder in Adults

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

See Important Reminder at the end of this policy for important regulatory and legal information.

Subject: Pegvaliase-pqpz (Palynziq )

Clinical Policy: Dental Anesthesia Reference Number: CA.CP.MP.61

Transcription:

Electroconvulsive Therapy- ECT Policy: IEHP considers ECT medically necessary for members with the following disorders: 1. Unipolar and bipolar depression. 2. Bipolar mania. 3. Psychotic disorders including schizophrenia and schizoaffective disorder under certain conditions. Qualification Process: A course of ECT generally consists of six to twelve treatments over two to four weeks. Under certain conditions, maintenance ECT spanning several months or years is indicated. Primary indications: According to the American Psychiatric Association Task Force, ECT treatment could be prescribed as a first-line or primary treatment when a rapid or higher probability of response is needed and the patient symptomatology is severe. Situations would include, but are not limited to: 1. Primary or secondary severe major depression with/without psychotic features 2. Manic delirium 3. Acute mania 4. Catatonia 5. At risk for self harm or others 6. Medication-resistance or intolerance (i.e. anti-depressants and/or neuroleptic medications that pose a particular medical risk) 7. When ECT is safer than alternative treatments in conditions such as with the infirm elderly and during pregnancy Secondary indications: ECT treatment could be prescribed as a second-line or secondary treatment for patients that have the following, but are not limited to: 1. Poor or little response to other modalities of treatment 2. Deterioration in psychiatric condition 10801 Sixth St, Rancho Cucamonga, CA 91730 Tel (909) 890-2000 Fax (909) 890-2003 Visit our web site at: www.iehp.org A Public Entity

Page 2 of 6 3. Onset of suicidal ideations or intent to harm self or others 4. Lack of or decrease in the will to live (i.e. exhaustion, dehydration, lack of vigor) ECT Continuation or Maintenance: Continuation or maintenance ECT may be used to reduce the risk for relapse and recurrence of illness. Treatments may be started on a weekly basis with the interval treatments gradually extended to a month, depending on patient response. Patient referral for maintenance ECT should meet one or more of the following indications: 1. History of illness that is responsive to ECT 2. History of medication-resistant depression 3. Medication intolerance or patient unwillingness to take medication. 4. Co morbid conditions that complicate management of the psychiatric disorder 5. Either non-compliance or intolerance to pharmacotherapy 6. Patient preference for continuation ECT therapy; and 7. Ability and willingness of the patient to comply with overall treatment plan to prevent relapse Prior to initiating electroconvulsive therapy: 1. Psychiatric history and examination, including past response to ECT treatments, a baseline neuropsychiatric evaluation, and a second opinion regarding the medical necessity of ECT. 2. Medical evaluation that includes history and examination (i.e. neurological, cardiovascular, pulmonary systems, and previous response to anesthesia). 3. Review of dental problems including examining loose or missing teeth, presence of dentures or other appliances. 4. Laboratory and diagnostic tests. Conditions not covered: 1. Major depression and bipolar disorder when the patient tolerates and is responding to antidepressant medications. 2. Ability to tolerate effective antidepressant or psychotropic medications, and rapid resolution of depression is unnecessary because the patient is not an immediate risk of suicide. 3. No evidence of ECT effectiveness in patients who have been treated previously (e.g. use of bilateral electrode placement for a series of 12 treatments). 4. Alcoholism as the primary diagnosis.

Page 3 of 6 Other non-covered benefits: Multiple-Seizure Electroconvulsive Therapy (MECT). CPT Codes Covered: 90870 (ECT) 00104 (Anesthesia) CPT Codes Not Covered: 90871 (MECT) CMS: No National Coverage Determination (NCD). No Local Coverage Determination (LCD) specific for California. LCD (L34595) covering forty states including Oregon and Arizona detailing coverage for depression, mania, and psychotic disorders, including many associated conditions. Guidelines for ECT presented in the LCD are consistent with the primary, secondary, and maintenance indications listed above. Medi-Cal: Medi-Cal reimburses for CPT codes 90870 (ECT) and 00104 (ECT related anesthesia). Medi- Cal Inpatient Mental Health Services Program makes provisions for ECT as part of an inpatient stay. DHCS: ECT treatments are voluntary unless a court has determined the patient lacks capacity to make decisions. Apollo: Electroconvulsive therapy may be indicated in selected cases of pathologically severe major depression, mania or exacerbations of some psychotic disorders. American Psychiatric Association Practice Guidelines: ECT is indicated in certain situations for Major Depressive Disorder, Bipolar Affective Disorder, and Schizophrenia. Aetna: Aetna considers ECT medically necessary for members diagnosed with any of the following conditions: catatonia, certain acute schizophrenic exacerbations, major depression (unipolar, bipolar, or mixed episode), and mania. Cigna: Cigna considers ECT medically necessary for depression, mania, catatonia, and psychotic disorders under certain circumstances.

Page 4 of 6 United Healthcare: The most common principal diagnostic indicators for ECT are: major depression, bipolar disorder, schizophrenia and other psychotic disorders. Anthem: ECT is considered medically necessary when diagnostic criteria for major depression, bipolar disorder, mood disorder, severe Parkinson s disease, organic catatonia, schizoaffective disorder or schizophrenia have been met. Medical Literature: ECT is well studied and documented to be an effective treatment for depression, mania, catatonia, and some psychotic disorders. In many cases, it is the most effective treatment known for these conditions and is considered the treatment of choice for treatment resistant depression, mania, catatonia, and specific psychotic disorders. According to FDA, the currently cleared ECT devices are indicated for severe depression, major depressive episode with melancholia, schizophrenia, bipolar disorder-depressed phase, bipolar disorder-manic phase, and catatonia, schizophreniform and schizoaffective disorder. Background: Electroconvulsive therapy is a procedure where electrodes are positioned on the patient s scalp, and measured electrical current is passed through to the brain. ECT is effective for a narrow range of psychiatric disorders. It is effective for mood disorders both bipolar and unipolar. It can also be used to augment the treatment of schizoaffective disorder and schizophrenia. Most ECT is performed to treat depression and is not typically the first-line of treatment. However, ECT works more quickly than medications and should be used as a first line treatment in life threatening catatonia or someone who is extremely suicidal. Research shows that ECT may be appropriate for patients with recurrences who were prior ECT responders and for refractory depression in patients with contraindications to medications or who are unwilling to take medications. When ECT is prescribed it should be part of a treatment plan overseen by a board certified psychiatrist in conjunction with other therapies when indicated. Effective Date: 02/10/16 Revised: Reviewed Annually:

Page 5 of 6 Bibliography: 1. Centers for Medicare & Medicaid Services, Local Coverage Determination (LCD): Electroconvulsive Therapy (ECT) (L34595), CMS.gov, 2015. 2. Centers for Medicare & Medicaid Services, National Coverage Determination (NCD) for Multiple Electroconvulsive Therapy (MECT) (160.25), CMS.gov, 2003. 3. Inpatient Mental Health Services Program, Inpatient Services Medi-Cal Update, Bulletin 492, September 2015. 4. Medi-Cal Rates Information, Medi-Cal Rates as of 11/15/2015 (Codes 87850 thru 94772). 5. Medi-Cal Rates Information, Medi-Cal Rates as of 11/15/2015 (Codes 00100 thru 14001). 6. Rights for Individuals in Mental Health Facilities, DHCS Handbook, Revised May 2014. 7. Bischel, Margaret D., Electroconvulsive Therapy (ECT), Managing Behavioral Healthcare Fourth Edition, Apollo Managed Care Consultants, 2013. 8. ECT for Major Depressive Disorder (MDD) Practice Guidelines, American Psychiatric Association, 2010. 9. ECT for Bipolar Affective Disorder Practice Guidelines, American Psychiatric Association, 2002. 10. ECT for Schizophrenia Practice Guidelines, American Psychiatric Association, 2004. 11. Aetna, Electroconvulsive Therapy Policy No. 0445, 2015. 12. Cigna, Standards and Guidelines/Medical Necessity Criteria for Treatment of Behavioral Health and Substance Use Disorders, Revised 2015. 13. United Healthcare, Electroconvulsive Therapy Level of Care Guidelines, 2012. 14. Anthem Blue Cross, Adult Mental Health Services, Inpatient/Outpatient Electroconvulsive Therapy, 2013. 15. ECRI Institute, Electroconvulsive Therapy for Treating Mental Health Disorders, December 2015.

Page 6 of 6 Disclaimer IEHP Clinical Authorization Guidelines (CAG) are developed to assist in administering plan benefits, they do not constitute a description of plan benefits. The Clinical Authorization Guidelines (CAG) express IEHP's determination of whether certain services or supplies are medically necessary, experimental and investigational, or cosmetic. IEHP has reached these conclusions based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). IEHP makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in the Clinical Authorization Guidelines (CAG). IEHP expressly and solely reserves the right to revise the Clinical Authorization Guidelines (CAG), as clinical information changes.